| Literature DB >> 35631375 |
Nashwah G M Attallah1, Fatma Alzahraa Mokhtar2, Engy Elekhnawy3, Selim Z Heneidy4, Eman Ahmed5,6, Sameh Magdeldin6,7, Walaa A Negm8, Aya H El-Kadem9.
Abstract
Methotrexate (MTX) is widely used in the treatment of numerous malignancies; however, its use is associated with marked hepatotoxicity. Herein, we assessed the possible hepatoprotective effects of Salvinia auriculata methanol extract (SAME) against MTX-induced hepatotoxicity and elucidated the possible fundamental mechanisms that mediated such protective effects for the first time. Forty mice were randomly allocated into five groups (eight/group). Control saline, MTX, and MTX groups were pre-treated with SAME 10, 20, and 30 mg/kg. The results revealed that MTX caused a considerable increase in blood transaminase and lactate dehydrogenase levels, oxidative stress, significant activation of the Nod-like receptor-3 (NLPR3)/caspase-1 inflammasome axis, and its downstream inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). MTX also down-regulated nuclear factor erythroid 2-related factor 2 (Nrf2) expression. Additionally, it increased the immunostaining of nuclear factor kappa-B (NF-κB) and downstream inflammatory mediators. Furthermore, the hepatic cellular apoptosis was dramatically up-regulated in the MTX group. On the contrary, prior treatment with SAME significantly improved biochemical, histopathological, immunohistochemical alterations caused by MTX in a dose-dependent manner. The antibacterial activity of SAME has also been investigated against Acinetobacter baumannii clinical isolates. LC-ESI-MS/MS contributed to the authentication of the studied plant and identified 24 active constituents that can be accountable for the SAME-exhibited effects. Thus, our findings reveal new evidence of the hepatoprotective and antibacterial properties of SAME that need further future investigation.Entities:
Keywords: Acinetobacter baumannii; LC-ESI-MS/MS; NLPR3; SEM; inflammasome; oxidative stress
Year: 2022 PMID: 35631375 PMCID: PMC9145932 DOI: 10.3390/ph15050549
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Phytochemical profiling of SAME by LC-ESI-MS/MS in negative and positive mode.
| No. | Rt (min) | Precursor | Error ppm | Metabolite Name | Formula | Adduct | MS/MS Spectrum | Class |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.36 | 179.034 | 0.5 | Caffeic acid | C9H8O4 | [M-H]− | 107.050 [C7H5O+2H]−, 117.034 [C8H6O]−H−, 135.045 [C8H7O2]− | Hydroxy |
| 2 | 1.42 | 181.049 | 0.4 | Caffeic acid | C9H8O4 | [M+H]+ | 53.002 [C3H2O−H]+, 122.036 [C7H6O2]+, 137.059 [C8H7O2+H]+H+, 163.038 [C9H7O3]+ | Hydroxy |
| 3 | 2.14 | 169.097 | 0.1 | Pyridoxamine | C8H12N2O2 | [M+H]+ | 70.065 [C4H6N+H]+H+, 86.060 [C4H7NO]+H+, 124.063 [C6H6N2O+H]+H+ | Pyridoxamine 5’-phosphates |
| 4 | 3.76 | 341.086 | 5.3 | Esculin | C15H16O9 | [M+H]+ | 108.02 [C6H3O2]+H+, 123.007 [C6H3O3]+, 137.023 [C7H3O3+H]+H+, 151.060 [C5H10O5]+H+, 179.055 [C6H11O6]+ | Coumarin |
| 5 | 4.22 | 147.045 | 0.1 | Trans- | C9H8O2 | [M-H]− | 77.039 [C6H5]−, 103.055 [C8H7]−, 119.050 [C8H6O+H]− | Cinnamic acids |
| 6 | 4.747 | 195.087 | −0.8 | Caffeine | C8H10N4O2 | [M+H]+ | 110.071 [C5H7N3]+H+, 138.066 [C6H7N3O]+H+, 151.037 [C6H4N3O2]+H+ | Xanthines |
| 7 | 5.01 | 154.049 | −0.8 | 3-hydroxy | C7H7NO3 | [M+H]+ | 94.02 [C6H4O+H]+H+, 112.03 [C5H5NO2]+H+, 122.02 [C7H4O2+H]+H+, 140.03 [C6H6NO3]+ | Hydroxy |
| 8 | 5.07 | 177.019 | −0.6 | 6,7-dihydroxy coumarin | C9H6O4 | [M-H]− | 77.039 [C6H4+H]−, 105.034 [C7H4O+H]−, 133.029 [C8H6O2]−H−, 149.024 [C8H6O3]−H− | 6,7-dihydroxy coumarins |
| 9 | 5.198 | 355.102 | −0.9 | Chlorogenic acid (3-caffeoylquinic acid) | C16H18O9 | [M+H]+ | 89.02 [C3H4O3]+H+, 117.018 [C4H6O4−H]+, 135.044 [C8H7O2]+, 145.049 [C6H10O4−H]+, 163.038 [C9H7O3]+, 337.091 [C16H17O8]+ | Quinic acids and derivatives |
| 10 | 5.296 | 179.033 | 0.6 | 6,7-dihydroxycoumarin (esculetin) | C9H6O4 | [M+H]+ | 51.02 [C4H3]+, 77.03 [C6H5]+, 105.03 [C7H5O]+, 123.04 [C7H6O2]+H+, 133.02 [C8H5O2]+, 135.02 [C8H5O2+H]+H+, 151.0 [C8H6O3]+H+ | 6,7-dihydroxy coumarins |
| 11 | 5.3 | 179.033 | 0.6 | Daphnetin | C9H6O4 | [M+H]+ | 77.038 [C6H4]+H+, 104.997 [C6H3O2−2H]+, 123.007 [C6H4O3−H]+, 133.028 [C8H6O2−H]+, 135.044 [C8H6O2]+H+, 151.038 [C8H6O3]+H+ | 7,8-dihydroxy coumarins |
| 12 | 5.352 | 353.087 | −0.4 | Chlorogenic acid | C16H18O9 | [M-H]− | 111.045 [C6H5O2+2H]−, 135.045 [C8H7O2]−, 161.024 [C9H7O3−H]−H−, 173.045 [C7H11O5−H]−H−, 179.035 [C9H7O4]−, 191.0561 [C7H11O6]− | Quinic acids and derivatives |
| 13 | 6.172 | 255.065 | −0.8 | Daidzein | C15H10O4 | [M+H]+ | 91.017 [C6H4O−H]+, 131.049 [C9H5O+H]+H+, 181.028 [C12H6O2−H]+, 182.036 [C12H6O2]+, 199.038 [C12H7O3]+, 219.044 [C15H8O2−H]+, 237.054 [C15H9O3]+ | Isoflavones |
| 14 | 7.16 | 193.049 | −0.1 | Scopoletin | C10H8O4 | [M+H]+ | 77.038 [C6H4]+H+, 122.036 [C7H6O2]+, 133.028 [C8H5O2]+, 137.059 [C8H7O2+H]+H+, 150.031 [C8H5O3]+H+, 178.026 [C9H5O4]+H+ | 7-hydroxy |
| 15 | 7.65 | 433.112 | 4.5 | Apigenin 8-C-glucoside (vitexin) | C21H20O10 | [M+H]+ | 239.0346 [C11H11O6]+, 267.0287 [C12H11O7]+, 295.0241 [C13H11O8]+, 313.0346 [C13H14O9−H]+ | Flavonoid 8-C-glycosides |
| 16 | 8.32 | 447.092 | 1.4 | Baicalein-7- | C21H18O11 | [M+H]+ | 117.069 [C9H6+2H]+H+, 239.033 [C14H9O4−2H]+, 267.049 [C12H9O7+H]+H+, 295.044 [C13H11O8]+, 313.055 [C13H11O9+H]+H+ | Flavonoid-7- |
| 17 | 8.41 | 463.088 | 0.7 | 6-hydroxy | C21H20O12 | [M-H]− | 301.035 [C15H9O7]−, 315.051 [C16H10O7+H]−, 343.045 [C17H12O8]−H−, 403.067 [C19H16O10]−H− | Flavonoid-3- |
| 18 | 8.68 | 195.065 | −0.2 | Trans-ferulic acid | C10H10O4 | [M+H]+ | 63.02 [C5H4−H]+, 79.05 [C5H3O]+, 117.03 [C8H6O−H]+, 135.04 [C8H6O2]+H+, 145.02 [C9H6O2−H]+, 163.03 [C9H7O3]+ | Hydroxy |
| 19 | 8.76 | 449.108 | 0.3 | Cyanidin 4″-glucoside | C21H21O11 | [M] + | 147.065 [C6H10O4]+H+, 252.062 [C12H14O6−2H]+, 273.096 [C12H15O7+H]+H+ | Anthocyanidin |
| 20 | 9.742 | 287.055 | 0.9 | Luteolin | C15H10O6 | [M+H]+ | 135.044 [C8H6O2]+H+, 153.018 [C7H4O4]+H+, 215.070 [C13H8O3+2H]+H+, 255.065 [C15H8O4+2H]+H+, 269.044 [C15H9O5]+ | Flavones |
| 21 | 10.52 | 269.045 | 0.6 | Apigenin | C15H10O5 | [M-H]− | 117.034 [C8H6O]−H−, 149.024 [C8H5O3]−, 183.045 [C12H6O2+H]−, 225.055 [C14H9O3]−, 227.035 [C13H9O4−H]-H−, 254.058 [C15H9O4+H]− | Flavones |
| 22 | 10.76 | 211.132 | −0.3 | (+-)-Jasmonic acid | C12H18O3 | [M+H]+ | 81.1 [C6H10−H]+, 123.1 [C8H10O]+H+, 147.03 [C11H17−2H]+, 157.1 [C8H11O3+H]+H+, 165.1 [C11H17O]+ | Jasmonic acids |
| 23 | 10.88 | 271.060 | 0.9 | Apigenin | C15H10O5 | [M+H]+ | 119.08 [C8H6O]+H+, 153.02 [C7H4O4]+H+, 253.14 [C15H9O4]+ | Flavones |
| 24 | 10.89 | 271.060 | 0.9 | Genistein | C15H10O5 | [M+H]+ | 119.049 [C8H6O]+H+, 153.018 [C7H4O4]+H+, 243.065 [C12H10O4]+, 253.049 [C15H9O4]+ | Isoflavones |
Figure 1Mass/Mass spectra showing fragmentation pattern of major identified compounds. (A) Trans-ferulic acid, 6,7-dihydroxy coumarin vitexin, and baicalein-7-O-glucuronide. (B) Daphnetin, esculin, scopoletin, and chlorogenic acid. * mean precursor ion (m/z).
Antimicrobial resistance profile of A. baumannii isolates.
| Isolate Number | Resistance Profile * | Isolate Number | Resistance Profile * |
|---|---|---|---|
| A1 | CEF- SXT-GEN-AMK | A15 | CEF-SXT-CIP |
| A2 | CEF-CXM-TOB-CIP | A16 | CXM-TET-CHL-CIP |
| A3 | CXM-GEN-CHL | A17 | CEF-SXT-GEN |
| A4 | AZM-TET | A18 | SXT-GEN-AMK-TOB |
| A5 | TET-CHL | A19 | CEF-CXM-CAZ-SXT-GEN-CIP-CHL |
| A6 | CEF-CXM-CHL-CIP-LVX | A20 | AMK-CHL |
| A7 | CAZ-SXT-GEN-TET | A21 | CEF-CXM-CAZ-GEN |
| A8 | SXT-TET-CHL | A21 | GEN-AMK-TOB-TET-CHL |
| A9 | CEF-CXM-SXT | A22 | CEF |
| A10 | TET | A23 | CXM-AZM-TET |
| A11 | AZM-CHL | A24 | CAZ-GEN-AZM-CIP-LVX |
| A12 | SXT-GEN-AMK | A25 | CXM-TET-CHL |
| A13 | AMK-AZM-CHL | A26 | CEF |
| A14 | CEF-CXM-SXT-CHL-CIP-IPM | A27 | CXM-AZM-CHL |
* Cephalothin: CEF, cefuroxime: CXM, ceftazidime: CAZ, cotrimoxazole: SXT, gentamicin: GEN, amikacin: AMK, tobramycin: TOB, azithromycin: AZM, tetracycline: TET, chloramphenicol: CHL, ciprofloxacin: CIP, levofloxacin: LVX, and imipenem: IPM.
Figure 2An illustrative example for the significant decrease in the membrane integrity in A. baumannii isolate (A1) after treatment with SAME.
Figure 3An illustrative example of A. baumannii isolate (A1) shows a significant rise in (A) the outer membrane permeability and (B) the inner membrane permeability after treatment with SAME.
Figure 4An illustrative example for the isolate (A1), showing a significant rise in the protein concentration after treatment with SAME.
Figure 5Scanning electron image showing the morphology of a representative A. baumannii isolate (A1): (A) before and (B) after treatment with SAME.
Effects of SAME Pre-treatment on serum indices of hepatotoxicity in MTX-induced hepatotoxicity in mice.
| Alanine Amino | Aspartate Amino Transferase (AST) | Lactate | |
|---|---|---|---|
| Control | 41.77 ± 4.8 | 69.08 ± 10.2 | 66.82 ± 8.6 |
| MTX | 53.98 ± 6.25 a | 153.87 ± 12.5 a | 131.98 ± 9.6 a |
| SAME 10 | 51.26 ± 3.8 | 141.78 ± 8.35 | 118.87 ± 10.7 |
| SAME 20 | 46.92 ± 8.1 | 132.53 ± 7.36 b | 88.25 ± 5.9 b |
| SAME 30 | 42.67 ± 4.5 bc | 78.33 ± 8.31 bcd | 72.78 ± 3.6 bcd |
Hepatotoxicity was induced by a single intraperitoneal (I.P) injection of MTX (20 mg/kg). SAME 10, 20, and 30 were given orally once daily for 5 consecutive days and a single injection of MTX on the sixth day. Data expressed as mean ± standard deviation (SD) (n = 8/group). Significant difference vs. a respective control, b respective MTX group, c respective SAME 10, group, d respective SAME 20 group each at p < 0.05.
Effects of the SAME Pre-treatment on hepatic MDA level, hepatic NO content, and hepatic SOD activity in MTX-induced hepatotoxicity in mice.
| Hepatic MDA Content (nm/gm Tissue) | Hepatic NO Content (nmol/g Tissue) | Hepatic SOD Activity (U/mg Tissue) | |
|---|---|---|---|
| Control | 148 ± 12.2 | 12.7 ± 1.35 | 2.95 ± 0.18 |
| MTX | 230 ± 13.95 a | 33.2 ± 3.1 a | 2.1 ± 0.28 a |
| SAME 10 | 210 ± 7.34 | 27.1 ± 2.6 | 2.35 ± 0.31 |
| SAME 20 | 185 ± 10.4 b | 21.6 ± 1.92 b | 2.7 ± 0.21 b |
| SAME 30 | 158 ± 6.51 bc | 14.2 ± 0.98 bcd | 3.05 ± 0.41 bcd |
Hepatotoxicity was induced by a single I.P injection of MTX (20 mg/kg). SAME 10, 20 and 30 were given orally once daily for 5 consecutive days and a single injection of MTX on the sixth day. Data expressed as mean ± SD (n = 8/group). Significant difference vs. a respective control, b respective MTX group, c respective SAME 10, group, d respective SAME 20 group each at p < 0.05.
Figure 6Effect of the SAME pre-treatment on the expression of NLPR3 in the liver tissues. (A) Representative western blot bands of NLPR3/β-actin (B) Graphical presentation of NLPR3 expression level in hepatic tissue. Hepatotoxicity was induced by a single I.P injection of MTX (20 mg/kg). SAME 10, 20 and 30 were given orally once daily for 5 consecutive days and a single injection of MTX on the sixth day. Data expressed as mean ± SD (n = 8/group) as the experiments were performed in three independent triplicates. Significant difference vs. a respective control, b respective MTX group, c respective SAME 10 group, each at p < 0.05.
Figure 7Effect of the SAME pre-treatment on (A) Hepatic caspase-1 gene expression level (B) Hepatic IL-1β level (C) Hepatic IL-18 gene expression level. Hepatotoxicity was induced by a single I.P injection of MTX (20 mg/kg). SAME 10, 20 and 30 were given orally once daily for 5 consecutive days and a single injection of MTX on the sixth day. Data expressed as mean ± SD (n = 8/group). Significant difference vs. a respective control, b respective MTX group, c respective SAME 10 group, d respective SAME 20 group each at p < 0.05.
Figure 8Effect of the SAME pre-treatment on (A) Nrf-2 expression level (B) Caspase-3 expression level. Hepatotoxicity was induced by a single I.P injection of MTX (20 mg/kg). SAME 10,20 and 30 were given orally once daily for 5 consecutive days and a single injection of MTX on the sixth day. Data expressed as mean ± SD (n = 8/group). Significant difference vs. a respective control, b respective MTX group, c respective SAME 10 group, d respective SAME 20 group each at p < 0.05.
Figure 9Effects of the SAME pretreatment on immunohistochemical staining of NF-κB. (A) A section in the liver of the normal control group showed negative immunostaining in hepatocytes (nuclear positivity in less than 1% of hepatocytes) (red arrows) [×200]. (B) A section in the liver of the MTX group showed positive nuclear staining in more than 10% of hepatocytes score 2 (red arrows) [×200]. (C) A section in the liver of the SAME 10 pretreated group showed positive nuclear staining in more than 10% of hepatocytes score 2 (red arrows) [×200]. (D) A section in the liver of the SAME 20 pretreated group showed positive nuclear staining in 1–10% of hepatocytes score 1 (red arrows) [×200]. (E) A section in the liver of the SAME 30 pretreated group showed negative immunostaining in hepatocytes (nuclear positivity in less than 1% of hepatocytes) (red arrows) [×200]. (F) Percentage of positive cells/1000 cells per 10 high power fields. Data expressed as mean ± SD. Significant difference vs. a respective control, b respective MTX group, c respective SAME 10 group, d respective SAME 20 group each at p < 0.05.
Figure 10Histopathological examination of the liver sections stained with hematoxylin and eosin (H&E). (A) A section in the liver of the control group showed portal tract (portal venule, hepatic arteriole, and bile ductule) (black arrow) surrounded by cords of hepatocytes (red arrows) [H&E × 200]. (B): Section in the liver of MTX group showed congested central vein (red arrow), dilated portal venule, and hepatic arteriole (blue arrows) surrounded by cords of hepatocytes showing focal necrosis (black arrows) [H&E × 100]. (C): Section in the liver of MTX group showed portal tract showing chronic inflammatory cellular infiltrate (black arrow) surrounded by cords of hepatocytes showing hydropic degeneration (blue arrows) and focal necrosis (red arrows) [H&E × 200]. (D): Section in the liver of SAME 10 group showed average-sized central veins (black arrows) surrounded by cords of average-sized hepatocytes, some of which showed hydropic degeneration (red arrows) [H&E × 200]. (E): Section in the liver of the SAME 20 group showed mild dilated portal venule (black arrow) surrounded by a few chronic inflammatory (blue arrow) surrounded by cords of average-sized hepatocytes with no necrosis or degeneration [H&E × 100]. (F): Section in the liver of the SAME 30 group showed an average-sized central vein (blue arrow) surrounded by cords of hepatocytes (red arrow) with no necrosis, degeneration, or inflammation [H&E × 200].
Semi-quantitative scoring shows the hepatoprotective effects of SAME.
| Histological Parameters | Normal Control | MTX | SAME 10 | SAME 20 | SAME 30 |
|---|---|---|---|---|---|
| Hepatoportal and sinusoidal congestion | - | +++ | + | + | - |
| Hydropic degeneration | - | +++ | ++ | + | - |
| Cellular necrosis | - | +++ | ++ | + | - |
| Apoptosis | - | +++ | + | + | - |
| Inflammatory cellular infiltrate | - | +++ | ++ | + | - |
- sign indicating no effect, + indicates mild effect, ++ indicates moderate effect, +++ indicates severe effect.